SCHEMBL827727

SCHEMBL827727

CCOC(=O)Cn1nc(Nc2ccc3c(c2)OC(F)(F)O3)nc1-c1ccnc(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.42
▸ TSHR P16473 2/20 0.37
▸ P2RX3 P56373 1/20 0.36
▸ BRAF P15056 6/20 0.36
▸ KIT P10721 5/20 0.36
▸ MAPT P10636 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ XBP1 P17861 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ ADORA3 P0DMS8 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ ADORA2B P29275 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ SYK P43405 1/20 0.34
▸ ALOX5 P09917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL827495 0.92 CYP1A2 (0.43) CYP1A2TSHRBRAFKITADORA3
SCHEMBL2340465 0.89 CYP1A2 (0.39) CYP1A2TSHRP2RX3BRAFMAPT
SCHEMBL827698 0.89 CYP1A2 (0.41) CYP1A2P2RX3BRAFKITMAPT
SCHEMBL12450325 0.86 CYP1A2 (0.42) CYP1A2TSHRP2RX3BRAFMAPT
SCHEMBL827668 0.85 CYP1A2 (0.38) CYP1A2P2RX3BRAFKITKDM4E
SCHEMBL827757 0.82 TSHR (0.41) TSHRMAPTGAAPOLBALDH1A1
SCHEMBL827708 0.81 CYP1A2 (0.42) CYP1A2P2RX3BRAFKITMAPT
SCHEMBL827578 0.80 CYP1A2 (0.41) CYP1A2BRAFKITMAPTPOLB
SCHEMBL2343983 0.78 ADORA3 (0.38) CYP1A2P2RX3BRAFKITMAPT
SCHEMBL827982 0.76 CYP1A2 (0.39) CYP1A2P2RX3BRAFKITKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143419-B2 Trisubstituted 1,2,4-triazoles JANSSEN PHARMACEUTICA N. V. (BE) 2012-03-27 — — US disclosed
US-8143419-B2 Trisubstituted 1,2,4-triazoles JANSSEN PHARMACEUTICA N. V. (BE) 2012-03-27 — — US disclosed
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-08 — — US disclosed
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES CHRNA1, CHRNA5, CHRNA3 CYP1A2 438/4885TSHR 88/4885P2RX3 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback